Goldman Sachs Maintains Buy on Intellia Therapeutics, Lowers Price Target to $136
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Salveen Richter has maintained a Buy rating on Intellia Therapeutics (NASDAQ:NTLA) but has reduced the price target from $157 to $136.

November 10, 2023 | 4:05 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Goldman Sachs maintains a Buy rating on Intellia Therapeutics but lowers the price target to $136 from $157.
While the reduction in price target could suggest a more conservative outlook on the stock's future performance, the maintenance of a Buy rating indicates continued confidence in the company's prospects. The impact on the stock price is likely to be mixed in the short term, as the market digests both the positive endorsement and the lowered expectations.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100